Treatment of age-related macular degeneration

Journal of the Royal Society of Medicine

Volumn 97, Issue 4, 2004, Pages 166-169

  Browning, Andrew C ^a   Amoaku, Winfried M ^a   Dua, Harminda S ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANECORTAVE; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BENZOPORPHYRIN DERIVATIVE; BETA CAROTENE; GLUCOCORTICOID; MINERALOCORTICOID; PHOTOSENSITIZING AGENT; PLACEBO; RANIBIZUMAB; STEROID; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN APTAMER ANTIBODY; VASCULOTROPIN INHIBITOR; WARFARIN; ZINC;

ANGIOGENESIS; CONJUNCTIVITIS; COST EFFECTIVENESS ANALYSIS; DIODE; DISEASE CLASSIFICATION; HEALTH CARE COST; HUMAN; HYPERTHERMIC THERAPY; INFRARED RADIATION; LASER; LASER COAGULATION; MACULAR RELOCATION SURGERY; PHOTODYNAMIC THERAPY; PUPIL; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; REVIEW; STROKE; SUBRETINAL NEOVASCULARIZATION; SUPPLEMENTATION; SURGICAL TECHNIQUE; TREATMENT INDICATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 1942456621     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.97.4.166     Document Type: Review

References (26)

1. Klein R, Klein BEK, Linton KLP. Prevalence of age related maculopathy, The Beaver Dam Eye Study. Ophthalmology 1992;99: 933-43
2. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age related maculopathy in Australia. Ophthalmology 1995;102:14-5060
3. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology 1995; 102:205-10
4. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomised clinical trials. Arch Ophthalmol 1991;109:1109-14
5. Macular Photocoagulation Study Group. Recurrent choroidal neovascularisation after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 1986;104:503-12
6. Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. BMJ 2003;326:485-8
7. A randomised, placebo-controlled clinical trial of high dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS report No 8. Arch Ophthalmol 2001;119:1417-36
8. Young RW. Solar radiation and age related macular degeneration. Surv Ophthalmol 1988;32:252-69
9. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-34
10. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 1993; 111:1200-9
11. Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularisation in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000;117:327-36
12. Photodynamic therapy of subfoveal choroidal neovascularisation in age related macular degeneration with verteporfin. One year results of 2 randomised clinical trials - TAP report 1. Arch Ophthalmol 1999;117: 1329-45
13. Photodynamic therapy of subfoveal choroidal neovascularization in age related macular degeneration with verteporfin. Two year results of 2 randomised clinical trials - TAP report 2. Arch Ophthalmol 2001;119: 198-207
14. Photodynamic therapy of subfoveal choroidal neovascularization in age related macular degeneration with verteporfin. Three year results of an open label extension of 2 randomised clinical trials - TAP report No 5. Arch Ophthalmol 2002;120:1307-14
15. Verteporfin therapy of subfoveal choroidal neovascularization in age related macular degeneration: two-year results of a randomised clinical trial including lesions with occult with no classic choroidal neovascularisation - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60
16. Sharma S. Update in retina: photodynamic therapy for the treatment of subfoveal choroidal neovascularisation secondary to age related macular degeneration. Can J Ophthalmol 2001;36:7-10
17. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Ophthalmology 2001;108:2051-9
18. Meads C, Sales C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical Effectiveness and Cost Utility of Photodynamic Therapy for Wet Age-related Macular Degeneration. Birmingham: West Midlands Technology Assessment Group, University of Birmingham, 2002
19. Fujii GY, De Juan E, Pieramici DJ, et al. Inferior limited macular translocation for subfoveal choroidal neovascularisation: 1-year visual outcome and recurrence report. Am J Ophthalmol 2002;134:69-74
20. Aisenbrey S, Lafaut B, Szurman P, et al. Macular translocation with 360° retinotomy for exudative age related macular degeneration. Arch Ophthalmol 2002;120:451-9
21. Ciulla TA. Recent advances in the treatment of exudative age related macular degeneration, including transpupillary thermotherapy. Acta Ophthalmol Scand 2003;81:103-4
22. Algvere PV, Libert C, Lindgarde G, Seregard S. Transpupillary thermotherapy of predominantly occult choroidal neovascularisation in age related macular degeneration with 12 months follow-up. Acta Ophthalmol Scand 2003;81:110-17
23. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularisation with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46
24. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration, phase II study results. Ophthalmol 2003;110:979-86
25. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularisation in age related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110:2372-85
26. Gillies MC, Simpson JM, Luo W, et al. A randomised clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age related macular degeneration. Arch Ophthalmol 2003;121: 667-73